Clinical trial
A Single-center, Open-label, Single-dose Ascending Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of HHT201 (Donepezil Dihydroxynaphthalate for Injection) in Healthy Subjects
NCT06373094 is registered in ClinicalTrials.gov with Shanghai Synergy Pharmaceutical Sciences Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Open-label, Single-dose Ascending Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of HHT201 (Donepezil Dihydroxynaphthalate for Injection) in Healthy Subjects
- Lead sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- June 1, 2024
- Completion date
- March 31, 2025
- Enrollment
- 64 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.